RCUS Earnings & Financial Statements
Arcus Biosciences, Inc.
$23.83
-$0.69(-2.81%)
39
Overall
60
Value
20
Tech
39
Quality
Market Cap
$3.12B
Volume
1.86M
52W Range
$13.61 - $31.74
Target Price
$38.75
RCUS earnings and financial statements: Arcus Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RCUS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $247.00M | $258.00M | $117.00M | $112.00M | $383.00M |
| Operating income | -$386.00M | -$330.00M | -$340.00M | -$280.00M | $54.00M |
| EBITDA | -$328.00M | -$261.00M | -$283.00M | -$252.00M | $62.00M |
| Net income | -$353.00M | -$283.00M | -$307.00M | -$267.00M | $53.00M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B |
| Total liabilities | $508.00M | $665.00M | $633.00M | $688.00M | $750.00M |
| Shareholders’ equity | $631.00M | $485.00M | $462.00M | $657.00M | $842.00M |
| Cash and equivalents | $222.00M | $150.00M | $127.00M | $206.00M | $148.00M |
| Long-term debt | $99.00M | $48.00M | - | - | $116.89M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$482.00M | -$170.00M | -$306.00M | $438.00M | -$256.00M |
| Capital expenditure | -$2.00M | -$6.00M | -$24.00M | -$6.00M | -$26.00M |
| Free cash flow | -$484.00M | -$176.00M | -$330.00M | $432.00M | -$282.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RCUS | $23.83 | -2.8% | 1.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |